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Abstract
In colorectal cancer (CRC), WNT pathway activation by genetic
rearrangements of RSPO3 is emerging as a promising target.
However, its low prevalence severely limits availability of preclini-
cal models for in-depth characterization. Using a pipeline designed
to suppress stroma-derived signal, we find that RSPO3 “outlier”
expression in CRC samples highlights translocation and fusion
transcript expression. Outlier search in 151 CRC cell lines identified
VACO6 and SNU1411 cells as carriers of, respectively, a canonical
PTPRK(e1)-RSPO3(e2) fusion and a novel PTPRK(e13)-RSPO3(e2)
fusion. Both lines displayed marked in vitro and in vivo sensitivity
to WNT blockade by the porcupine inhibitor LGK974, associated
with transcriptional and morphological evidence of WNT pathway
suppression. Long-term treatment of VACO6 cells with LGK974 led
to the emergence of a resistant population carrying two frameshift
deletions of the WNT pathway inhibitor AXIN1, with consequent
protein loss. Suppression of AXIN1 in parental VACO6 cells by RNA
interference conferred marked resistance to LGK974. These results
provide the first mechanism of secondary resistance to WNT path-
way inhibition.
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Introduction
Most colorectal cancers display aberrant activation of the WNT
pathway, leading to stabilization and nuclear translocation of
b-catenin, a key transcriptional regulator controlling stem cell main-
tenance, proliferation, and differentiation (Krausova & Korinek,
2014). In a molecular survey carried out by The Cancer Genome
Atlas, 93% of CRCs have been found to carry a genetic alteration in
at least one of 16 WNT pathway genes, defining this pathway as a
major driver of CRC (Cancer Genome Atlas, 2012). In particular,
loss of function of the WNT pathway suppressor APC accounts for
70% of all CRCs. APC alterations typically occur at early steps of the
colorectal adenoma–carcinoma sequence (Powell et al, 1992; Morin
et al, 1997), a typical feature of “trunk” genetic events, present in
all cancer cells and therefore therapeutically attractive (Swanton,
2012). Accordingly, established CRCs were found to critically
depend on APC mutation-driven enhanced WNT signaling, even in
the presence of additional cancer-driving mutations (Dow et al,
2015). Genomic rearrangements involving the RSPO2 and RSPO3
genes have been found to provide an alternative mechanism of aber-
rant WNT pathway activation in CRC (Seshagiri et al, 2012). These
genes encode secreted proteins, R-spondins, that synergize with
WNT ligands to promote b-catenin signaling (de Lau et al, 2011).
RSPO2 and RSPO3 translocations are mutually exclusive with APC
mutations and lead to aberrant expression of fusion transcripts in
which the 50 portion, upstream from the RSPO coding sequence, is
typically contributed by the highly expressed EIF3E and PTPRK
genes, respectively (Seshagiri et al, 2012).
In the case of the PTPRK-RSPO3 translocation, recent studies in
patient-derived xenografts (PDXs) carrying the fusion transcript
demonstrated that inhibition of WNT ligand secretion by porcupine
blockade, or direct targeting of RSPO3 by antibodies, markedly inhi-
bits tumor growth, promoting loss of cancer stem cell functions and
differentiation (Chartier et al, 2016; Madan et al, 2016; Storm et al,
2016). These results highlight the clinical relevance of targeting
RSPO3 rearrangements in CRC patients. As for all pathway-targeted
therapies, availability of experimental models is crucial to character-
ize the dependency on pathway activators and to explore possible
mechanisms of release from such dependency (Misale et al, 2014;
Rosa et al, 2014). Indeed, mechanisms of acquired resistance to
WNT pathway inhibition are currently unexplored. In this view,
availability of established CRC cell lines spontaneously carrying
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RSPO3 fusions would provide a valuable resource. We recently
reported a large collection of 151 CRC cell lines and associated
global gene expression profiles, reliably representing the molecular
heterogeneity of CRC (Medico et al, 2015). We have also shown that
expression-based outlier analysis within this compendium leads to
identification of therapeutically actionable oncogenic drivers
(Medico et al, 2015). Considering that, in RSPO3 rearrangements, a
strong promoter is placed upstream of the RSPO3 coding sequence,
we hypothesized that searching for outlier RSPO3 expression might
pinpoint cases carrying the respective translocation. This hypothesis
was tested in RNA-seq-based expression data generated by the
TCGA, checking the presence of the RSPO3 fusion in outlier cases.
Outlier expression analysis was then extended to the 151 CRC cell
lines, leading to the identification of two unique lines carrying a
RSPO3 fusion. We employed these cell lines to investigate addiction
to WNT pathway activation mediated by PTPRK-RSPO3 trans-
locations, modeling primary sensitivity and acquired secondary
resistance.
Results and Discussion
Identification of RSPO3 rearrangements in CRC samples by
combined stroma/transcript expression analysis
PTPRK-RSPO3 rearrangements typically lead to aberrant expression
of fusion transcripts by colorectal cancer cells that normally do not
express RSPO3 (Sato et al, 2009; Seshagiri et al, 2012). Therefore,
in principle, searching for CRC samples displaying high RSPO3
mRNA levels should pinpoint tumors bearing RSPO3 fusions.
However, stromal cells have been identified as a source for RSPO3
expression in the intestine (Kabiri et al, 2014). To verify the stromal
origin of RSPO3 transcripts in CRC, we exploited the fact that in
CRC patient-derived xenografts (PDXs), human stroma is substi-
tuted by mouse stroma (Isella et al, 2015). Analysis of our previous
species-specific analysis of RNA-seq data from CRC PDXs (Isella
et al, 2015) revealed that the fraction of RSPO3 transcripts of mouse
origin is 99.9%. As a consequence, it is expected that in a human
CRC sample, RSPO3 mRNA levels are correlated with the richness
of stroma that we found to be reliably approximated by a transcrip-
tional cancer-associated fibroblast (CAF) score (Isella et al, 2015).
We therefore analyzed the correlation between the CAF score and
RSPO3 mRNA levels in a 450-sample human CRC RNA-seq expres-
sion dataset that we previously assembled from TCGA (Isella et al,
2015). As shown in Fig 1A, RSPO3 levels were highly correlated
with the CAF score (Pearson correlation = 0.76), confirming that
the expression of this gene in tumor samples is mostly due to stro-
mal cells. However, among the samples expressing high RSPO3
levels (red rectangle in Fig 1A), some had low CAF score, suggest-
ing a possible overexpression by epithelial cancer cells. Similar
results were also obtained using additional stromal scores, namely
the endothelial score and the leukocyte score (Appendix Fig S1).
We therefore selected all cases with RSPO3 expression Z-score > 2
and searched for RSPO3 fusions in the corresponding TCGA RNA-
seq data. A canonical PRPTK(ex1)-RSPO3(ex2) fusion transcript
was detected in 6 out of the 14 selected samples (43%). To test
whether RSPO3 fusions are enriched in samples with low stroma,
for each of the 450 TCGA samples, we subtracted the CAF score
from the RSPO3 expression value and found that in a subset of
samples, presenting low CAF score values and high RSPO3 expres-
sion, this delta value raises to Z-score levels usually observed for
outlier genes (Fig 1B). The relationship between RSPO3 levels and
CAF score was further validated in an independent 2140-sample
CRC microarray dataset, highlighting the presence of samples with
high RSPO3 expression not justified by abundant stroma
(Appendix Fig S2). In principle, RSPO3 fusions are expressed only
by cancer cells; therefore, outlier samples characterized by low CAF
score should be enriched in fusion transcripts. To test this hypothe-
sis, the 14 RSPO3 overexpressing samples described above were
subdivided in two groups, respectively, having a positive and a
negative delta (RSPO3-CAF score). Notably, the six RSPO3 fusions
were exclusively present in the positive delta group, also corre-
sponding to delta Z-score values higher than 2.5 (Fig 1B,
Appendix Table S1). To verify whether additional RSPO3 fusions
were present in samples not identified by the above approach, we
extended the search for RSPO3 fusions to 12 additional TCGA RNA-
seq samples expressing lower levels of RSPO3. In particular, for any
expression level, we selected samples with the lowest CAF score, so
that at least a fraction of the RSPO3 reads could theoretically derive
from epithelial cells (Appendix Fig S3). None of these samples was
found to carry a RSPO3 fusion, suggesting that our approach satu-
rated the dataset and captured all the samples carrying RSPO3 rear-
rangements. Samples with lower levels were not explored because
the limited number of expected RNA-seq reads covering RSPO3
would anyway not allow detection of reads covering a fusion
transcript. Cross-check with an available pan-cancer database of
fusion transcripts in TCGA samples (http://www.tumorfusions.org;
Yoshihara et al, 2015) revealed that no additional RSPO3 fusions were
detected in the 450-sample TCGA dataset used for our analysis.
These results show that the presence of RSPO3 rearrangements
in CRC can be anticipated by high RSPO3 mRNA levels not justified
by abundant stroma.
Transcriptional outlier analysis identifies CRC cell lines carrying
canonical and novel PTPRK-RSPO3 rearrangements
To search for established cell lines carrying RSPO3 rearrangements,
we analyzed RSPO3 expression levels in our previously described
compendium of 151 CRC cell lines (Medico et al, 2015). While, as
expected, RSPO3 expression was low or absent in most cells, two
lines, VACO6 and SNU1411, were found to markedly overexpress
RSPO3 (Fig 1C). Notably, both cell lines are wild type for APC, but
have a different molecular makeup: VACO6 are microsatellite insta-
ble and BRAF mutated (V600E); SNU1411 are microsatellite stable
and KRAS mutated (G12C). These mutations render both cells insen-
sitive to EGFR-blockade by cetuximab (Medico et al, 2015) and
therefore attractive models for alternative targeted therapy
approaches. The two lines have also different in vitro growth prop-
erties (Fig 1C, photo inserts): while SNU1411 form adherent colo-
nies (Ku et al, 2010), VACO6 cells, established from a poorly
differentiated cecal cancer, grow as aggregates in suspension
(McBain et al, 1984). RNA-seq analysis of the VACO6 and SNU1411
transcriptomes revealed a canonical PRPTK(ex1)-RSPO3(ex2) fusion
transcript in VACO6 (Fig 1D) and a novel PRPTK(ex13)-RSPO3(ex2)
fusion transcript in SNU1411 cells (Fig 1E). RNA-seq results were
further confirmed by PCR followed by Sanger sequencing
EMBO Molecular Medicine ª 2017 The Authors
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Figure 1. Identification of RSPO3 rearrangements in CRC samples and cell lines by outlier expression analysis.
A Scatter plot displaying the correlation between RSPO3 expression (x-axis) and CAF score (y-axis). The red box highlights samples with high RSPO3 expression and
variable CAF score. Empty dots indicate samples selected for fusion analysis. Empty dots with red border indicate samples with high RSPO3 levels and medium-low
CAF score.
B Dot plots displaying the distribution of Z-score values for RSPO3 alone (left panel) and RSPO3 minus CAF score (right panel) in the 450-sample TCGA dataset. Red dots
indicate RSPO3 fused samples. Empty dots indicate analyzed samples that do not carry fusions in the RSPO3 gene.
C Scatter plot displaying RSPO3 expression levels (Log2 signal, y-axis) in 151 CRC cell lines (left). Right images represents SNU1411 and VACO6 cell lines phase-contrast
micrographs.
D Canonical in-frame gene fusion between exon 1 of PTPRK and exon 2 of the RSPO3 gene revealed by RNA-seq analysis of VACO6 cells.
E Novel in-frame gene fusion between exon 13 of PTPRK and exon 2 of the RSPO3 gene revealed by RNA-seq analysis of SNU1411 cells.
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(Appendix Fig S4). The absence of reads covering exon 1 of RSPO3
confirmed that all RSPO3 transcripts detected in these cell lines orig-
inate from the fused transcript. These results highlight VACO6 and
SNU1411 cell lines as unique cell line models to characterize addic-
tion to WNT pathway activation by rearranged RSPO3 not only
in vivo, but also in vitro, in the absence of supporting stroma.
Cell lines carrying RSPO3 fusion transcripts are sensitive to
porcupine inhibition in vitro and in vivo
The vast majority of CRC are affected by loss-of-function mutations in
components of the destruction complex (e.g., APC) leading to accu-
mulation of b-catenin and constitutive activation of Wnt target genes.
RSPO3 instead promotes WNT pathway activation by binding the
LGR4/5 protein and neutralizing RNF43-mediated degradation of
LRP5/6 receptor, enhancing therefore the activity of WNT ligands
(de Lau et al, 2014). Therefore, pharmacological blockade of WNT
ligand secretion could be an effective strategy to target RSPO3-overex-
pressing cancer cells (Madan & Virshup, 2015). To this aim, we
considered the small molecule LGK974 that specifically inhibits the
porcupine (PORCN) acyltransferase, thus abrogating posttranslational
processing and secretion of WNT ligands (Krausova & Korinek, 2014).
LGK974 is currently being tested in humans, in phase 1 trials (Liu
et al, 2013). VACO6 and SNU1411 cells were tested for in vitro dose–
response to LGK974 and found to be both exquisitely sensitive, with
IC50 values below 50 nM (Fig 2A). As a control, HCT116 cells, that do
not carry RSPO3 rearrangements, were insensitive to PORCN inhibi-
tion (IC50 > 5 lM). As shown in Fig 2B, both cell lines responded to
LGK974 with marked apoptotic cell death and downregulation of the
WNT pathway, evaluated by quantitative reverse transcription PCR
(qRT–PCR) analysis of the WNT target gene AXIN2 (Drost et al, 2015;
Jho et al, 2002; see Materials and Methods). To evaluate in vivo sensi-
tivity of VACO6 and SNU1411 cells to WNT pathway inhibition,
immunocompromised mice were xenotransplanted and treated with
LGK974 or vehicle for 4 weeks. Xenotransplants of both cell lines
responded to LGK974 with sustained growth inhibition (> 90%) and
tumor stabilization (Fig 2C and D). Accordingly, tumors explanted at
the end of the treatment displayed dramatic reduction in proliferating
cells, and mucinous differentiation (Fig 2E and F), confirming that the
in vivo response of both cell lines to WNT blockade phenocopies the
described differentiation and growth arrest observed in CRC patient-
derived xenografts (Storm et al, 2016). Altogether, these results show
that both CRC cell lines carrying RSPO3 fusions are addicted to WNT
signaling and sensitive to the porcupine inhibitor LGK974 in vitro and
in vivo. Moreover, both models completely recapitulate morphofunc-
tional traits of response previously described for RSPO3 blockade
(Madan & Virshup, 2015; Storm et al, 2016). This is particularly inter-
esting for SNU1411 cells with the noncanonical RSPO3 fusion, in
which the long upstream coding sequence from PTPRK does not seem
to lessen the pathological activation of WNT pathway driven by aber-
rant RSPO3 expression.
AXIN1 frameshift deletions confer acquired resistance to WNT
pathway inhibition in RSPO3-addicted cells
VACO6 cells, carrying the most common RSPO3 fusion, were
subjected to long-term treatment with incremental doses of LGK974
(see Materials and Methods), which was found to generate
secondary resistance within 3 months. In the meantime, parental
cells were maintained in culture without drug as a control. A viabil-
ity assay demonstrated that selected cells were completely resistant
to LGK974 (IC50 > 10 lM), while control parental cells maintained
their sensitivity (Fig 3A). Copy number analysis based on exome
sequencing of LGK974-resistant and parental VACO6 cells only high-
lighted minor changes of no clear functional meaning: trisomy of
chromosome 8 and heterozygous deletion from 13q21.39 to
13q31.1. Moreover, a series of additional indels/mutations with
high allelic frequency were detected (Appendix Table S2). In the
context of a MSI cell line, a large set of mutations at low allelic
frequency is expected as a consequence of genetic drift during
expansion. However, in this case, the number of concurrent muta-
tions at high allelic frequency points to the occurrence of a sepa-
rated clone, pre-existing to the selection process. Interestingly,
exome sequencing revealed that LGK974-resistant VACO6 (VACO6R)
cells diverged from the parental population by the presence of two
single-base deletions in the AXIN1 coding sequence (Fig 3B,
Appendix Fig S5), respectively, at position p.G265fs* (33 supporting
reads) and p.V835fs* (90 supporting reads). Both deletions are
reported in the COSMIC database (Forbes et al, 2015) as cancer-
related somatic variants (COSM1609260 and COSM2920077) and
the first one is predicted to be a truncating alteration (Cerami et al,
2012). Indeed, both mutations, detected as heterozygous in VACO6R
cells, induce a frameshift in the coding sequence, which is compati-
ble with a functionally homozygous AXIN1 loss of function. Accord-
ingly, Western blot analysis showed a dramatic reduction in AXIN1
protein expression in VACO6R cells (Fig 3C).
To verify whether the two AXIN1 mutations co-existed in the
same resistant clone, we isolated 14 independent clones from
VACO6R cells by limiting dilution. All clones displayed complete
loss of AXIN1 protein, as previously observed for VACO6R
(Appendix Fig S6). Accordingly, we found that both frameshift
mutations were present in all clones, each of them being heterozy-
gous (Appendix Fig S6), which suggests that the vast majority of
VACO6R cells emerged from one resistant subclone in which the
two AXIN1 alleles were independently inactivated.
The AXIN1 protein acts as a scaffold for the destruction complex,
in which GSK-3b phosphorylates b-catenin, leading to its ubiquitina-
tion and degradation. Therefore, loss of AXIN1 leads to stabilization
of b-catenin and aberrant activation of the WNT pathway (MacDon-
ald et al, 2009). Accordingly, VACO6R cells displayed enhanced
mRNA expression of the WNT target AXIN2 (Fig 3D). AXIN1 and
AXIN2 are considered to be functionally redundant (Chia &
Costantini, 2005); however, AXIN2 is not always able to compensate
for AXIN1 knockdown (Figeac & Zammit, 2015). Indeed, in the case
of VACO6R cells, the observed AXIN2 upregulation does not
effectively counteract the complete loss of AXIN1, which results in
overall enhancement of WNT signaling.
To validate AXIN1 loss as a mechanism of secondary resistance
to WNT pathway inhibition, we downregulated AXIN1 by RNA
interference in parental VACO6 cells. Transient transfection of
siRNAs against AXIN1 severely reduced AXIN1 protein expression
in VACO6 parental cells (Fig 3E) and rendered them markedly resis-
tant to LGK974 (Fig 3F). We verified by qRT–PCR that the RSPO3
fusion transcript was still expressed in VACO6R cells (Fig EV1A).
Accordingly, in the mirror experiment, VACO6R cells were trans-
duced with wild-type AXIN1 to levels comparable to parental cells
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Figure 2. VACO6 and SNU1411 cells are sensitive to the porcupine inhibitor LGK974 in vitro and in vivo.
A Dose–response cell viability assay on VACO6, SNU1411, and HCT116 cells treated with LGK974. Data are expressed as average  SD of six technical replicates from
one representative experiment.
B Effect of 1 lM LGK974 on apoptosis and WNT pathway activity in VACO6 and SNU1411 cells. Upper panel: percentage of viable cells (DAPI-negative & Annexin-
negative; y-axis) after 96 h in control medium or 1 lM LGK974; means  SDs from triplicate experiments. Asterisks represent significant differences measured by
Student’s t-test (two-sided), **P < 0.05; ***P < 0.001. VACO6 (LGK974 versus CTRL), P = 3.88E-05; SNU1411 (LGK974 versus CTRL), P = 5.54E-03. Lower panel:
qRT–PCR evaluation of AXIN2 mRNA after treatment with vehicle or 1 lM LGK974 for 24 h, as indicated. Data are expressed as means  RMSE of three technical
replicates from one representative experiment measured by Student’s t-test (two-sided), **P < 0.05 (0.006); ***P < 0.001). VACO6 (LGK974 versus CTRL),
P = 1.72E-03; SNU1411 (LGK974 versus CTRL), P = 6.12E-05.
C, D Tumor growth curves of PDXs from VACO6 and SNU1411 xenografts treated for 28 days with LGK974 (5 mg/kg; red line) or with vehicle (black line). Number of
replicates: 6 or 7, as indicated in the panels. Error bars indicate standard error of the mean (SEM) values.
E, F Micrographs of representative xenograft tumors derived from VACO6 (E) and SNU1411 (F) explanted at the end of treatment with vehicle or LGK974, stained with
Ki67 or PAS, as indicated. Scale bar, 50 lm.
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Figure 3. AXIN1 loss confers acquired resistance to PORCN inhibition in VACO6 cell lines.
A Cell viability assay of VACO6 and VACO6R cells after 6 days of treatment with LGK974. Data are expressed as average  SD of six technical replicates from one
representative experiment.
B Representative chromatograms of Sanger-sequenced PCR products confirming the two concurrent AXIN1 frameshift deletions (FS) in VACO6R cells.
C Western blot showing loss of the AXIN1 protein in VACO6R cells.
D Bar graph displaying relative mRNA levels of the WNT pathway target gene AXIN2, measured by qRT–PCR, in VACO6 and VACO6R cells. Two-sided Student’s t-test,
*P < 0.05, P = 1.42E-02. Data are expressed as means  SD of three technical replicates from one representative experiment.
E Western blot showing downregulation of the AXIN1 protein in VACO6 cells by RNAi.
F ATP-based assay measuring viability, after 6 days of LGK974 treatment, of VACO6 cells transiently transfected with control siRNA or with AXIN1 siRNA, as indicated.
Data are expressed as average  SD of six technical replicates from one representative experiment.
G Schematic representation of (i) how RSPO3 overexpression supports WNT-b-catenin signaling, (ii) how porcupine inhibition by LGK974 blocks b-catenin, and (iii) how
AXIN1 loss restores b-catenin signaling in the presence of LGK974.
Source data are available online for this figure.
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(VACO6RAXIN1FL; Fig EV1B), which led to reduction in WNT
signaling and reversion of resistance to LGK974 (Fig EV1C and D).
These results further confirmed the causative role of AXIN1 loss in
resistance to LGK974.
Genetic alterations leading to AXIN1 loss of function have been
described in colon and other cancer types, albeit at low frequency
(Satoh et al, 2000; Dahmen et al, 2001; Laurent-Puig et al, 2001;
Wu et al, 2001; Cancer Genome Atlas, 2012; Forbes et al, 2015). In
CRC, AXIN1 alterations typically occur between exon 1 and 5, where
the binding domains for APC, GSK3, and b-catenin are located
(Salahshor & Woodgett, 2005). In cell lines and transgenic mice,
overexpression of AXIN1 leads to increased b-catenin degradation
and attenuation of WNT signaling, supporting its tumor suppressor
activity (Kishida et al, 1998; Hsu et al, 2001).
To verify whether AXIN1 loss confers resistance to additional
WNT pathway inhibitors, we tested in vitro on VACO6 and VACO6R
cells the alternative porcupine inhibitor WNT-C59 and the tankyrase
inhibitor XAV939. While both WNT-C59 and XAV939 were effective
on VACO6 parental cells, they had no effect on VACO6R cells
(Appendix Fig S7A and B). To evaluate the pathway specificity of
resistance in VACO6R, we assessed their sensitivity to two
chemotherapeutic agents commonly used to treat CRC patients, the
antimetabolite 5-FU and the topoisomerase-I inhibitor SN38, and to
Pevonedistat, a NEDD-8 inhibitor preclinically validated in CRC, to
which parental VACO6 cells are markedly sensitive (Picco et al,
2017).
We found that parental and VACO6R cells display the same
pattern of response to all three compounds (Appendix Fig S7C–E),
indicating that AXIN1 loss confers resistance specifically to WNT
pathway inhibition.
As illustrated in Fig 3G, here we show that, in CRC cells with
RSPO3 fusions and wild-type APC, loss of AXIN1 by truncating
mutations can sustain WNT pathway activity and resistance to more
upstream pathway inhibitors, such as the PORCN inhibitor LGK974.
These results confirm that loss of AXIN1 can sustain WNT signaling
also in the presence of functional APC and in the absence of WNT
ligands, providing the first genetic mechanisms of secondary resis-
tance to WNT pathway inhibition. Indeed, the emergence of AXIN1
genetic inactivation after long-term treatment with porcupine inhibi-
tion of VACO6 cells strongly supports the idea that RSPO3-rear-
ranged CRCs are critically dependent on WNT signaling. Moreover,
as previously observed for the EGFR pathway (De Roock et al,
2010; Misale et al, 2014), both primary and secondary resistance to
blockade of a central switch in a key signaling pathway can be
achieved by genetic alterations affecting downstream nodes of the
same pathway.
To further investigate whether AXIN1 inactivation is the only
way for VACO6 cells to become resistant to LGK974, we transduced
them with an activated b-catenin or induced transient APC down-
regulation by RNA interference (Fig EV2A). In both cases, increased
nuclear b-catenin levels (Fig EV2B) led to increased basal WNT
pathway activation (Fig EV3A) and resistance to PORCN inhibition
by LGK974 (Fig EV3B). These results confirmed that also alternative
molecular alteration leading to WNT pathway activation, like APC
loss and b-catenin activating mutations, can confer resistance to
WNT pathway inhibition in CRC cells with RSPO3 rearrangements.
Indeed, APC or b-catenin mutations are frequent in CRC and poten-
tially expected as cause of primary and secondary resistance to
WNT pathway inhibitors. Conversely, AXIN1 alteration is less
frequent and, in the clinical setting, would not be explored as first
candidate to confer acquired resistance. In this context, AXIN1 loss
could potentially drive also primary resistance to more upstream
WNT pathway inhibitors.
Materials and Methods
Cell lines, drugs, and generation of resistant cells
HCT116 were purchased from American Type Culture Collection
(ATCC), SNU1411 cells were purchased from Korean Cell Line Bank
(KCLB), and VACO6 cells were provided by Prof. Markovitz (Cleve-
land, USA). All cell lines were maintained in their original culturing
conditions according with supplier guidelines, as reported elsewhere
(Medico et al, 2015). Cells were ordinarily supplemented with fetal
bovine serum at different concentrations, 2 mM L-glutamine, antibi-
otics (100 U/ml penicillin and 100 mg/ml streptomycin), and grown
in a 37°C and 5% CO2 air incubator. Cells were routinely screened
for the absence of mycoplasma contamination using the Venor GeM
Classic kit (Minerva Biolabs). The identity of each cell line was
checked by Cell ID System and by Gene Print 10 System (Promega).
LGK974, WNT-C59, and SN-38 were purchased from Selleck Chemi-
cals (Cat. No. S7143, S07037, and S4908, respectively), and the
stock solution was prepared according to the manufacturer’s
guidelines. MLN4924 was obtained from Active Biochem (Cat. No.:
A-1139), while XAV-939 and 5-FU were purchased from Sigma (Cat.
No. X3004 and F6627).
VACO6 cells resistant to LGK974 were obtained by exposing
parental cells to escalating doses of LGK974 until resistant popula-
tion emerged (~3 months). In particular, cells were maintained in
50 nM LGK974 for 2 weeks, 100 nM for 2 weeks, 500 nM for
3 weeks, and subsequently maintained in 1 lM of LGK974.
Activated b-catenin and 7TGP reporter plasmids were purchased
from Addgene (https://www.addgene.org) Cat. No. 24313 and Cat.
No. 24305, respectively. Plasmids were purified with Maxiprep kits
(Invitrogen), and DNA concentration was measured by Nanodrop
1000. All lentiviral constructs were transfected into HEK293T cells
plated in a 6-well plate at a density of 5 × 104 cells per well 1 day
prior to transfection, using Lipofectamine 2000 (Invitrogen). Super-
natants were harvested after 48 h, filtered through a 0.45-lm filter,
and used to infect cells in the presence of 4 lg/ml of polybrene. After
transduction, cells were selected in puromycin (2 lg/ml for 7 days).
Gene expression datasets and stromal cell-specific signatures
To evaluate RSPO3 transcript expression in CRC samples, we
exploited our previously assembled 450-sample TCGA mRNA
dataset, available as Experiment Data package from Bioconductor:
http://www.bioconductor.org/packages/release/data/experiment/
html/TCGAcrcmRNA.html, as described elsewhere (Isella et al,
2015). To generate plots displayed in Appendix Fig S2, gene expres-
sion profiles from multiple datasets of CRC surgical specimens have
been assembled in a unique large dataset and analyzed (see Data
availability).
To accurately trace the stromal content from gene expression
profiles of bulk CRC tumor samples, we exploited three stromal
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signatures (for CAFs, leukocytes, and endothelial cells) that we
previously developed from sorted CRC cell populations (Isella et al,
2015). Averaging the expression of genes in each signature yielded
three stromal scores (CAF score, Leuco score, and Endo score,
respectively), reporting the abundance of the three stromal cell
populations in the sample.
RNA extraction, RNA-seq library preparation, and analysis
Total RNA was extracted from SNU1411 and VACO6 using
miRNeasy mini kit (Qiagen), according to the manufacturer’s proto-
col. The quantification and quality analysis of RNA were performed
on a 2100 Bioanalyzer (Agilent), using RNA 6000 nano Kit (Agilent).
RNA-seq libraries were generated using Illumina TruSeq Stranded
TotalRNA LT with Ribo-Zero Gold kit and validated using Bioana-
lyzer DNA 1000/High Sensitivity kit. Validated libraries were
normalized to 10 nM and pooled in equal volume. 75-nucleotide-
long single-end reads were performed on the NextSeq500 system
following vendor’s instruction.
Detection of RSPO3 fusion transcripts
TCGA level 1 unaligned Illumina RNA-seq FastQ files were obtained
from the Cancer Genomics Hub (https://browser.cghub.ucsc.edu).
Bioinformatic analyses to define the presence of fusion transcripts in
TCGA RNA-seq data were accomplished using Defuse (McPherson
et al, 2011) and ChimeraScan (Iyer et al, 2011) for paired-end
samples, while Mapsplice (http://www.netlab.uky.edu/p/bioinfo/
MapSplice2) was used for single-end samples. GRCh37/hg19
genome was used as reference for alignments in all tools. Parameter
settings are listed in Appendix Table S1B. Fusions in VACO6 and
SNU1411 were identified using of a combination of BWA (Li &
Durbin, 2010) and BLAT aligners (Kent, 2002). The reads potentially
containing translocations were extracted from the alignment files
and re-aligned using BLAT and then postprocessed to detect gene
rearrangements. Fusion calling was performed with the following
criteria: Each partner must have at least 25 mapped nucleotides on
the respective end of the read; the two partners must map to two
different genes.
Exome sequencing and analysis
Libraries for exome sequencing were prepared with the Nextera
Rapid Capture Exome Kit (Illumina, Inc.), according to the
manufacturer’s protocol. Preparation of libraries was performed
using 100 ng of genomic DNA from VACO6 and VACO6R cells,
fragmented using transposons, adding simultaneously adapter
sequences. Purified DNA was isolated after the fragmentation step
and used as a template for subsequent PCR to introduce unique
sample barcodes. Fragments’ size distribution of the DNA was
assessed using the 2100 Bioanalyzer with a High Sensitivity DNA
assay kit (Agilent Technologies). The same amount of DNA
libraries was pooled and subjected to hybridization capture.
Libraries were then sequenced using the Illumina NS500 sequencer
(Illumina, Inc.). FastQ files generated by Illumina NextSeq500
were preprocessed to remove all bases in the read with a Phred
quality score less than 20. Sequences were mapped to the human
reference (assembly hg19) using the BWA-mem algorithm bwa;
PCR duplicates were removed using the RMDUP command of
SAMtools package (Li et al, 2009). Mutational discovery analyses
were performed by a custom NGS pipeline, according to previously
published methods (Siravegna et al, 2015), in order to call genetic
variations in VACO6R respect to VACO6 cells, when supported by
at least 1.5% allelic frequency and 5% significance level obtained
with a Fisher test. To identify insertions and deletions (indels), we
further analyzed the alignment files by comparing VACO6 and
VACO6R cells using Pindel software (Ye et al, 2009). Mutations
and indels were annotated by a custom script printing out gene
information, number of normal and mutated reads, the allelic
frequencies, and the variation effect. Each of these entries was
associated with the corresponding number of occurrences in the
COSMIC database (Forbes et al, 2015).
Cell viability assay
CRC cell lines were seeded at different densities (2–4 × 103 cells per
well) in 50 ll complete growth medium in 96-well plastic culture
plates at day 0. The following day, serial dilutions of LGK974 were
added to the cells in additional 50 ll serum-free medium. Plates
were incubated at 37°C in 5% CO2 for 1 week, after which the cell
viability was assessed by measuring ATP content through Cell Titer-
Glo Luminescent Cell Viability assay (Promega). Luminescence was
measured by Perkin Elmer Victor X4. For RNA interference experi-
ments, cell viability was measured after 6 days of treatment.
Apoptosis
To evaluate the fraction of live cells, SNU1411 and VACO6 were
treated with 1 lM LGK974 for 96 h. Apoptosis was measured as
staining with APC-conjugated Annexin V (Bender MedSystems,
Burlingame, CA, USA) and DAPI (D9542, Sigma), in accordance
with the manufacturer’s instructions. The samples were analyzed
on CyAN-Adp flow cytometer (Dako, Carpinteria, CA USA). Data
acquisition was performed using Flow Jo Software.
RNA interference
The siRNA-targeting reagents were purchased from Dharmacon, as
a SMARTpool of four distinct siRNA species targeting different
sequences of the AXIN1 transcript (L-009625-00-0005) and the APC
transcript (L-003869-00-0005). Cell lines were grown and transfected
with SMARTpool siRNAs using RNAiMAX (Invitrogen) transfection
reagent, following manufacturer’s instructions. Each experiment
included the following controls: mock control (transfection lipid
only), siControl1 (Dharmacon), AllStars (Qiagen) as negative
control, and polo-like kinase 1 (Dharmacon), which served as posi-
tive control (Brough et al, 2011).
qRT–PCR
Total RNA was extracted using the miRNeasy Mini Kit (Qiagen),
according to the manufacturer’s protocol. The quantification and qual-
ity analysis of RNA were performed by Thermo Scientific Nanodrop
1000 and 2100 Bioanalyzer (Agilent). DNA was transcribed using
iScript RT Super Mix (Bio-Rad) following the manufacturer’s instruc-
tions. qRT–PCR was performed in triplicate on ABI PRISM 7900HT
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thermal cycler (Life Technologies) with SYBR green dye. The mRNA
expression levels of the AXIN2 and the APC genes were normalized
respect to PGK expression. Differential expression was statistically
assessed by Student’s t-test, although the limited group size (n = 3)
does not allow reliable estimate of normality, which is commonly
accepted for qPCR. The sequences of the primers (Sigma-Aldrich)
used for gene expression analyses are as follows: AXIN2_FW,
50-CGGGCATCTCCGGATTC-30, AXIN2_RV, 50-TCTCCAGGAAAGTTC
GGAACA-30, APC_FW 50-GAAGGTCAAGGAGTGGGAGA-30, APC_RV
50-CTTCGAGGTGCAGAGTGTGT-30, and PGK_FW, 50-AGCTGCTGGG
TCTGTCATCCT-30, PGK_RV, 50-TGGCTCGGCTTTAACCTTGT-30.
Western blot
Prior to biochemical analysis, 1.5 × 106 cells were grown in their
specific media supplemented with 10% FBS. Total cellular proteins
were extracted by solubilizing the cells in EB buffer (50 mM HEPES
pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM
EDTA, 2 mM EGTA; all reagents were from Sigma-Aldrich, except
for Triton X-100 from Fluka) in the presence of 1 mM sodium ortho-
vanadate, 100 mM sodium fluoride, and a mixture of protease inhi-
bitors. Extracts were clarified by centrifugation and normalized with
the BCA Protein Assay Reagent kit (Thermo). Primary antibodies
used were against AXIN1 antibody (Cell Signaling, C76H11—
Cod.BK2087S) and anti-actin (Santa Cruz). Signals were revealed
after incubation with anti-mouse or anti-rabbit secondary antibodies
coupled to peroxidase (Amersham) by using enhanced chemilumi-
nescence (ECL, Amersham).
Animal models
Female NOD-SCID mice (Charles River Laboratories) were used in all
in vivo studies. All animal procedures were approved by the Ethical
Committee of the Institute and by the Italian Ministry of Health. The
methods were carried out in accordance with the approved guide-
lines. Nonobese diabetic/severe combined immunodeficient (NOD/
SCID) male mice were purchased from Charles River Laboratories
(Calco, Italy), maintained in hyperventilated cages, and manipulated
under pathogen-free conditions. In particular, mice were housed in
individually sterilized cages, every cage contained a maximum of 7
mice and optimal amounts of sterilized food, water, and bedding.
VACO6 and SNU1411 xenografts were established by subcutaneous
inoculation of 2 × 106 cells into the right posterior flank of 5- to 6-
week-old mice. Tumor size was evaluated without blinding by
caliper measurements, and the approximate volume of the mass was
calculated using the formula (d/2)2 × D/2, where d is the minor
tumor axis and D is the major tumor axis. When tumors reached an
average size of approximately 250 mm3, animals with the most
homogeneous size were selected and randomized by tumor size.
Vehicle or LGK974 (Cat. No. S7143; Selleck Chemicals), resuspended
in 0.5% MC/0.5% Tween-80, were subcutaneously administered to
mice 5 mg/kg daily. At least 6 mice for each experimental group
were used to allow reliable estimation of within-group variability.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissues explanted from cell xeno-
grafts were partially sectioned (10-lm thick) using a microtome.
4-lm paraffin tissue sections were dried in a 37°C oven overnight.
Slides were deparaffinized in xylene and rehydrated through graded
alcohol to water. Endogenous peroxidase was blocked in 3%
hydrogen peroxide for 30 min. Microwave antigen retrieval was
carried out using a microwave oven (750 W for 10 min) in
10 mmol/l citrate buffer, pH 6.0. Slides were incubated with mono-
clonal mouse anti-human Ki67 (1:100; Dako) overnight at 4°C inside
a moist chamber. After washings in TBS, anti-mouse secondary
antibody (Dako Envision+System horseradish peroxidase-labeled
polymer, Dako) was added. Incubations were carried out for 1 h at
room temperature. Immunoreactivities were revealed by incubation
in DAB chromogen (DakoCytomation Liquid DAB Substrate
Chromogen System, Dako) for 10 min. Slides were counterstained
in Mayer’s hematoxylin, dehydrated in graded alcohol, and cleared
in xylene, and the coverslip was applied by using DPX. A negative
control slide was processed with secondary antibody, omitting
primary antibody incubation. Immunohistochemically stained slides
for Ki67 were scanned with a 20× objective, and representative
images were been acquired. Periodic acid-Schiff (PAS) staining was
purchased by Bio-Optica (Cat. No. 04-130802), and the staining
was performed following the manufacturer’s instructions.
Immunofluorescence
Cells, grown on glass coverslip, were fixed in 4% paraformaldehyde
for 20 min at room temperature and permeabilized with 0.1%
Triton X-100 in PBS for 2 min on ice. Then, cells were treated at
room temperature with 1% BSA in PBS for 30 min and incubated
for 2 h at room temperature with the primary anti-b-catenin
antibody (Purified Mouse Anti-b-Catenin, Cat. No. 610154, BD
Transduction LaboratoriesTM) diluted in PBS containing 1% donkey
The paper explained
Problem
Colorectal cancer (CRC) is currently treated mainly by chemotherapy
and, when possible, anti-EGFR targeted therapy. Recently, gene
fusions involving the R-spondin family members RSPO2 and RSPO3
have been identified in CRC. These alterations promote WNT pathway
activation and can be targeted by WNT pathway inhibitors. In this
context, the understanding of the mechanisms of sensitivity and resis-
tance to this new therapeutic strategy is limited by the lack of avail-
ability of preclinical models featuring these specific alterations.
Results
By expression outlier analysis, we found two CRC cell lines, VACO6
and SNU1411, overexpressing RSPO3 and carrying, respectively, a
canonical and a novel rearrangement of RSPO3. Both lines were extre-
mely sensitive, in vitro and in vivo, to WNT blockade by PORCN inhi-
bition. Long-term PORCN inhibition of VACO6 led to secondary
resistance, driven by loss-of-function alterations of the AXIN1 gene,
encoding a suppressor of WNT signaling.
Impact
The newly identified RSPO3-rearranged stable cell lines provide a
useful preclinical model for characterizing sensitivity and resistance to
WNT pathway inhibitors in CRC. As an initial exploitation of this
model, we identified and validated AXIN1 genetic inactivation as the
first described mechanism of secondary resistance to WNT pathway
blockade.
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serum. After washing, cells were fluorescently labeled, according to
the primary antibody used, with anti-mouse-647 (A-21236, Thermo-
Fisher) diluted 1:400 in PBS containing 1% donkey serum for 1 h.
Nuclei were stained with DAPI. Coverslips were then mounted using
the fluorescence mounting medium (Dako, Glostrup, DK) and
analyzed using a confocal laser scanning microscope (TCS SPE II;
Leica, Wetzlar, D) equipped with 63×/1.40 oil immersion objective.
Flow cytometry
GFP expression analysis of in vitro cultured cells was performed by
flow cytometry: Cells were trypsinized, diluted in a 1%
paraformaldehyde-2% FBS solution, stained with DAPI (D9542,
Sigma), and analyzed with FACS flow cytometer (CyAnTM, DAKO).
Data availability
The following datasets, available in the Gene Expression Omnibus
(GEO) database, were used in this study: GSE59857 (Medico et al,
2015), GSE14333 (Jorissen et al, 2009), GSE35896 (Schlicker et al,
2012), GSE37892 (Laibe et al, 2012), GSE20916 (Skrzypczak et al,
2010), GSE17536 (Smith et al, 2010), GSE13294 (Jorissen et al,
2008), GSE39582 (Marisa et al, 2013), and GSE2109 (http://www.
intgen.org/research-services/biobanking-experience/expo/). KFSYSCC
was from https://www.synapse.org/#!Synapse:syn4974668.
Expanded View for this article is available online.
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